Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry, James H Peace, Jeanette A Stewart, William C Stewart, J Charles Henry, James H Peace, Jeanette A Stewart, William C Stewart

Abstract

Purpose: To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension.

Design: Prospective, multi-center, historical control study.

Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening. Patients were re-evaluated 3 months later.

Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores compared to either latanoprost or bimatoprost (p < 0.0001). Patients having any baseline OSD symptoms (n = 235) demonstrated significant improvement after switching to travoprost BAK-free (p < 0.0001). In 70.2% of these patients, symptoms were reduced in severity by at least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure (IOP) was significantly decreased (p < 0.0001). Overall, 72.4% preferred travoprost BAK-free (p < 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p < 0.0001).

Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control.

Keywords: benzalkonium chloride; bimatoprost; glaucoma; latanoprost; ocular surface disease; preservative; prostaglandin analog; travoprost.

Figures

Figure 1
Figure 1
Improvement in ocular surface disease index scores with travoprost BAK-free according to previous prostaglandin analog use. *p

Figure 2

Improvement in ocular surface disease…

Figure 2

Improvement in ocular surface disease index scores with travoprost BAK-free according to baseline…

Figure 2
Improvement in ocular surface disease index scores with travoprost BAK-free according to baseline severity. *p

Figure 3

Clinically significant improvement (≥9 points)…

Figure 3

Clinically significant improvement (≥9 points) in ocular surface disease index scores with travoprost…

Figure 3
Clinically significant improvement (≥9 points) in ocular surface disease index scores with travoprost BAK-free according to baseline severity.

Figure 4

Change in mean IOP with…

Figure 4

Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use.…

Figure 4
Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use. *p

Figure 5

Change in mean hyperemia scores…

Figure 5

Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog…

Figure 5
Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog use. *p
Similar articles
Cited by
References
    1. Astin M, Stjernschantz J, Selén G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59:401–7. - PubMed
    1. Baudouin C, Riancho LM, Warnet JM, et al. In vitro studies of anti-glaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123–8. - PubMed
    1. Book SA. Essentials of statistics. New York: McGraw-Hill; 1978. pp. 117–22.
    1. Epstein SP, Chen D, Asbell PA. The effect of travoprost Z, latanoprost and their individual components on the ocular surface (corneal and conjunctival epithelium). Presented at the Association for Research in Vision and Ophthalmology (ARVO); May 7, 2008; Fort Lauderdale, FL.
    1. Fechtner R, Budenz D, Godfrey D. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Poster presented at: Annual meeting of the American Glaucoma Society; March 8, 2008; Washington DC. 2008.
Show all 21 references
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 2
Figure 2
Improvement in ocular surface disease index scores with travoprost BAK-free according to baseline severity. *p

Figure 3

Clinically significant improvement (≥9 points)…

Figure 3

Clinically significant improvement (≥9 points) in ocular surface disease index scores with travoprost…

Figure 3
Clinically significant improvement (≥9 points) in ocular surface disease index scores with travoprost BAK-free according to baseline severity.

Figure 4

Change in mean IOP with…

Figure 4

Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use.…

Figure 4
Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use. *p

Figure 5

Change in mean hyperemia scores…

Figure 5

Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog…

Figure 5
Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog use. *p
Similar articles
Cited by
References
    1. Astin M, Stjernschantz J, Selén G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59:401–7. - PubMed
    1. Baudouin C, Riancho LM, Warnet JM, et al. In vitro studies of anti-glaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123–8. - PubMed
    1. Book SA. Essentials of statistics. New York: McGraw-Hill; 1978. pp. 117–22.
    1. Epstein SP, Chen D, Asbell PA. The effect of travoprost Z, latanoprost and their individual components on the ocular surface (corneal and conjunctival epithelium). Presented at the Association for Research in Vision and Ophthalmology (ARVO); May 7, 2008; Fort Lauderdale, FL.
    1. Fechtner R, Budenz D, Godfrey D. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Poster presented at: Annual meeting of the American Glaucoma Society; March 8, 2008; Washington DC. 2008.
Show all 21 references
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 3
Figure 3
Clinically significant improvement (≥9 points) in ocular surface disease index scores with travoprost BAK-free according to baseline severity.
Figure 4
Figure 4
Change in mean IOP with travoprost BAK-free according to previous prostaglandin analog use. *p

Figure 5

Change in mean hyperemia scores…

Figure 5

Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog…

Figure 5
Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog use. *p
Similar articles
Cited by
References
    1. Astin M, Stjernschantz J, Selén G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59:401–7. - PubMed
    1. Baudouin C, Riancho LM, Warnet JM, et al. In vitro studies of anti-glaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123–8. - PubMed
    1. Book SA. Essentials of statistics. New York: McGraw-Hill; 1978. pp. 117–22.
    1. Epstein SP, Chen D, Asbell PA. The effect of travoprost Z, latanoprost and their individual components on the ocular surface (corneal and conjunctival epithelium). Presented at the Association for Research in Vision and Ophthalmology (ARVO); May 7, 2008; Fort Lauderdale, FL.
    1. Fechtner R, Budenz D, Godfrey D. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Poster presented at: Annual meeting of the American Glaucoma Society; March 8, 2008; Washington DC. 2008.
Show all 21 references
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 5
Figure 5
Change in mean hyperemia scores with travoprost BAK-free according to previous prostaglandin analog use. *p

References

    1. Astin M, Stjernschantz J, Selén G. Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. Exp Eye Res. 1994;59:401–7.
    1. Baudouin C, Riancho LM, Warnet JM, et al. In vitro studies of anti-glaucomatous prostaglandin analogues: travoprost with and without benzalkonium chloride and preserved latanoprost. Invest Ophthalmol Vis Sci. 2007;48:4123–8.
    1. Book SA. Essentials of statistics. New York: McGraw-Hill; 1978. pp. 117–22.
    1. Epstein SP, Chen D, Asbell PA. The effect of travoprost Z, latanoprost and their individual components on the ocular surface (corneal and conjunctival epithelium). Presented at the Association for Research in Vision and Ophthalmology (ARVO); May 7, 2008; Fort Lauderdale, FL.
    1. Fechtner R, Budenz D, Godfrey D. Prevalence of ocular surface disease symptoms in glaucoma patients on IOP-lowering medications. Poster presented at: Annual meeting of the American Glaucoma Society; March 8, 2008; Washington DC. 2008.
    1. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17:217–22.
    1. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–9.
    1. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sof Zia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339–43.
    1. Kuppens EV, de Jong CA, Stolwijk TR, et al. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br J Ophthalmol. 1995;79:339–42.
    1. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98–103.
    1. Manni G, Centofanti M, Oddone F, et al. Interleukin-1beta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers. Am J Ophthalmol. 2005;139:72–7.
    1. McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs with or without benzalkonium chloride. J Ocul Pharmacol Ther. 2007;23:445–51.
    1. Miller KL, Mink DR, Mathias SD, et al. Estimating the minimal clinical important difference of the Ocular Surface Disease Index®: preliminary findings [abstract] 2006 Abstract obtained from .
    1. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–6.
    1. Ozcura F, Aydin S, Helvaci MR. Ocular surface disease index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm. 2007;15:389–93.
    1. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–23.
    1. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723–8.
    1. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.
    1. Whitson JT, Cavanagh HD, Lakshman N, et al. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663–71.
    1. Yee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther. 2006;23:511–9.
    1. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18:134–9.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe